These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 26589433)
1. Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients. Sinha D; Chong L; George J; Schlüter H; Mönchgesang S; Mills S; Li J; Parish C; Bowtell D; Kaur P; Clin Cancer Res; 2016 Apr; 22(7):1813-24. PubMed ID: 26589433 [TBL] [Abstract][Full Text] [Related]
2. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277 [TBL] [Abstract][Full Text] [Related]
3. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis. Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542 [TBL] [Abstract][Full Text] [Related]
4. Long Non-coding RNA Yim GW; Kim HJ; Kim LK; Kim SW; Kim S; Nam EJ; Kim YT Cancer Res Treat; 2017 Jul; 49(3):656-668. PubMed ID: 27737536 [TBL] [Abstract][Full Text] [Related]
5. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Takahashi Y; Koyanagi T; Suzuki Y; Saga Y; Kanomata N; Moriya T; Suzuki M; Sato Y Mol Cancer Res; 2012 Sep; 10(9):1135-46. PubMed ID: 22826464 [TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer. Hu L; Cong L Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668 [TBL] [Abstract][Full Text] [Related]
7. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer. Tucker DW; Getchell CR; McCarthy ET; Ohman AW; Sasamoto N; Xu S; Ko JY; Gupta M; Shafrir A; Medina JE; Lee JJ; MacDonald LA; Malik A; Hasselblatt KT; Li W; Zhang H; Kaplan SJ; Murphy GF; Hirsch MS; Liu JF; Matulonis UA; Terry KL; Lian CG; Dinulescu DM Clin Cancer Res; 2018 Mar; 24(6):1389-1401. PubMed ID: 29263182 [No Abstract] [Full Text] [Related]
8. Sterol regulatory element-binding protein 1 is required for ovarian tumor growth. Nie LY; Lu QT; Li WH; Yang N; Dongol S; Zhang X; Jiang J Oncol Rep; 2013 Sep; 30(3):1346-54. PubMed ID: 23818099 [TBL] [Abstract][Full Text] [Related]
9. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer. Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500 [TBL] [Abstract][Full Text] [Related]
10. Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancer. Xie H; Wang W; Sun F; Deng K; Lu X; Liu H; Zhao W; Zhang Y; Zhou X; Li K; Hou Y Sci Rep; 2017 Aug; 7(1):9896. PubMed ID: 28852147 [TBL] [Abstract][Full Text] [Related]
11. High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer. Sopo M; Sallinen H; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Anttila M PLoS One; 2020; 15(11):e0241484. PubMed ID: 33151982 [TBL] [Abstract][Full Text] [Related]
12. Xu Z; Zhuang L; Wang X; Li Q; Sang Y; Xu J Future Oncol; 2020 Sep; 16(25):1921-1930. PubMed ID: 32915667 [No Abstract] [Full Text] [Related]
13. Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival. Corvigno S; Wisman GB; Mezheyeuski A; van der Zee AG; Nijman HW; Åvall-Lundqvist E; Östman A; Dahlstrand H Oncotarget; 2016 Apr; 7(14):18573-84. PubMed ID: 26918345 [TBL] [Abstract][Full Text] [Related]
14. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma. Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740 [TBL] [Abstract][Full Text] [Related]
15. The potential prognostic value of cathepsin D protein in serous ovarian cancer. Chai Y; Wu W; Zhou C; Zhou J Arch Gynecol Obstet; 2012 Aug; 286(2):465-71. PubMed ID: 22476353 [TBL] [Abstract][Full Text] [Related]
16. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival. Gu Y; Li F; Qian N; Chen X; Wang H; Wang J J Clin Pathol; 2016 May; 69(5):448-53. PubMed ID: 26468391 [TBL] [Abstract][Full Text] [Related]
17. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Yang G; Rosen DG; Liu G; Yang F; Guo X; Xiao X; Xue F; Mercado-Uribe I; Huang J; Lin SH; Mills GB; Liu J Clin Cancer Res; 2010 Aug; 16(15):3875-86. PubMed ID: 20505188 [TBL] [Abstract][Full Text] [Related]
18. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. Medrano M; Communal L; Brown KR; Iwanicki M; Normand J; Paterson J; Sircoulomb F; Krzyzanowski P; Novak M; Doodnauth SA; Saiz FS; Cullis J; Al-Awar R; Neel BG; McPherson J; Drapkin R; Ailles L; Mes-Massons AM; Rottapel R Cell Rep; 2017 Mar; 18(10):2343-2358. PubMed ID: 28273451 [TBL] [Abstract][Full Text] [Related]
19. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers. Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759 [TBL] [Abstract][Full Text] [Related]
20. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Cheon DJ; Tong Y; Sim MS; Dering J; Berel D; Cui X; Lester J; Beach JA; Tighiouart M; Walts AE; Karlan BY; Orsulic S Clin Cancer Res; 2014 Feb; 20(3):711-23. PubMed ID: 24218511 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]